Market Signal Briefing

Citi has raised its price target on Nvidia (NASDAQ: NVDA) to $220 from $210 while maintaining a ‘Buy' rating, as analyst Atif Malik anticipates strong third-quarter results and higher guidance supported by surging AI-related demand.

ADENTRA Inc. (ADEN:CA) Q3 2025 Earnings Call November 10, 2025 11:00 AM EST

Company Participants

Robert Brown - President, CEO & Non-Independent Director
Faiz Karmally - VP, CFO & Secretary

Conference Call Participants

Kyle McPhee - Cormark Securities Inc., Research Division
Hamir Patel - CIBC Capital Markets, Research Division
Frederic Tremblay - Desjardins Securities Inc., Research Division
Zachary Evershed - National Bank Financial, Inc., Research Division
Jonathan Goldman - Scotiabank Global Banking and Markets, Research Division

Presentation

Operator

Good morning. My name is Joanna, and I will be your conference operator today. I would like to welcome everyone to the ADENTRA Third Quarter 2025 Results Conference Call.

[Operator Instructions]

With me on the call are Rob Brown, ADENTRA's President and CEO; and Faiz Karmally, Vice President and CFO. ADENTRA's third quarter 2025 earnings release, financial statements, MD&A and other quarterly filings are available on the Investors section of our website at www.adentragroup.com. These statements have also been filed on a entrust profile on SEDAR at www.sedar+.ca.

I want to remind listeners that management's comments during this call may include forward-looking statements. These statements involve various known and unknown risks and uncertainties and are based on management's current expectations and beliefs, which may prove to be incorrect. Actual results could differ materially from those described in these forward-looking statements.

Please refer to the tax in ADENTRA's earnings press release and financial filings for a discussion of the risks and uncertainties associated with these forward-looking statements. All dollar figures referred to today are in U.S. dollars unless stated otherwise.

I would now like to turn the call over to Rob Brown. Please go ahead.

Robert Brown
President, CEO & Non-Independent Director

Thanks, and good morning, everyone. We delivered strong results in the third quarter, highlighting the resilience and consistency of ADENTRA's operating model. We grew sales, adjusted EBITDA and maintained strong

Recommended For You

Global Ship Lease, Inc. (GSL) Q3 2025 Earnings Call November 10, 2025 10:30 AM EST

Company Participants

Thomas A. Lister - Chief Executive Officer
Georgios Youroukos - Executive Chairman
Tassos Psaropoulos - CFO & Treasurer

Conference Call Participants

Liam Burke - B. Riley Securities, Inc., Research Division
Omar Nokta - Jefferies LLC, Research Division

Presentation

Operator

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Global Ship Lease Third Quarter 2025 Earnings Conference Call. [Operator Instructions]

It is now my pleasure to turn today's call over to Thomas Lister, CEO of Global Ship Lease. Sir, the floor is yours.

Thomas A. Lister
Chief Executive Officer

Thank you very much. Hello, everyone, and welcome to the Global Ship Lease Third Quarter 2025 Earnings Conference Call. You can find the slides that accompany today's presentation on our website at www.globalshiplease.com.

As usual, Slides 2 and 3 remind you that today's call may include forward-looking statements that are based on current expectations and assumptions and are, by their nature, inherently uncertain and outside of the company's control. Actual results may differ materially from these forward-looking statements due to many factors, including those described in the safe harbor section of the slide presentation.

We would also like to direct your attention to the Risk Factors section of our most recent annual report on our 2024 Form 20-F, which was filed in March 2025. You can find the form on our website or on the SEC. All of our statements are qualified by these and other disclosures in our reports filed with the SEC. We do not undertake any duty to update forward-looking statements. The reconciliations of the non-GAAP financial measures to which we will refer during this call to the most

Recommended For You

Brent Penter, of Raymond James, has upgraded shares to Buy from Hold. His price target is $52.

Key Takeaways Schwab stock gained 1.7% after unveiling a $660M all-cash deal to acquire Forge Global.The acquisition enhances Schwab's access to private markets for retail and advisor clients.Schwab plans to integrate Forge's platform to boost transparency and expand investor access.
Charles Schwab (SCHW - Free Report) shares gained 1.7% following its announcement of an agreement to acquire Forge Global Holdings, Inc. (FRGE - Free Report) on Nov. 6. The all-cash transaction is valued at roughly $660 million.

 Forge Global, based in California, offers accredited investors a broad range of direct or indirect opportunities to engage in the private markets. Its combination of a direct marketplace, private company solutions and proprietary data helps enhance private market access and transparency for qualified investors.

FRGE operates the premier private market platform and a leading trading marketplace through which investors have traded more than $17 billion in private company shares as of Sept. 30, 2025.

Details of the Forge Global Buyout by SchwabPer the agreement, Schwab will pay $45 per share in cash for each share of Forge Global. The merger agreement has been approved by the board of directors of both entities.

Schwab expects the Forge Global transaction to be completed in the first half of 2026, subject to customary closing conditions.

Following the close, Schwab will begin offering Forge Global’s products to select ultra-high-net-worth clients, introduce ’40 Act funds to broaden private-market access and continue enhancing the integrated platform. In the near term, the company plans to extend access to more than 1 million retail clients and registered investment advisers, with further expansion to all qualified investors and enhanced stock-plan and proprietary solutions over the medium term.

Rationale Behind Acquisition Pursued by SCHWThis move aligns with Schwab’s strategy to offer private market capabilities to retail and advisor clients, leveraging its comprehensive suite of wealth, advisory, and investment management solutions, to address the complex needs of investors.

This addition of direct access to private securities through Forge Global builds on the recently launched Schwab Alternative Investments Select, an alternative investments platform available for retail clients with more than $5 million in household assets at Schwab. This move aims to capitalize on the sustained momentum in private markets, given the rising investor demand for early exposure to fast-growing startups to achieve greater returns and portfolio diversification.

Rick Wurster, president and CEO of Schwab, stated, “Access to Schwab’s 46 million client accounts and $11.6 trillion in client assets creates a strong distribution platform for private securities. With the pool of private companies growing and remaining private for longer, a leading platform for individual investors to participate in private markets offers durable, strategic value. We expect meaningful growth in this space and believe our platform will become a go-to venue where retail investors discover new investment opportunities.”

This acquisition aligns with Schwab’s strategy to diversify its revenue streams. As transactional activity improves in the private market, it will drive a surge in revenues for Schwab. In sync with this, earlier this month, the company introduced Schwab Private Issuer Equity Services, a complete equity management solution designed to help private companies in the late stages before an initial public offering.

Schwab’s Zacks Rank & Price PerformanceShares of Schwab have risen 22.3% in the past year compared with the industry’s 27.2% growth.

Image Source: Zacks Investment Research

SCHW currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Expansion Efforts by Other Finance FirmsLast month, Huntington Bancshares Incorporated (HBAN - Free Report) agreed to acquire Cadence Bank, a regional financial institution with $53 billion in assets headquartered in Houston, TX and Tupelo, MS.

The transaction is expected to be 10% accretive to Huntington’s earnings per share, mildly dilutive to regulatory capital at close, and 7% dilutive to tangible book value per share, with an earn-back period of about three years, including merger expenses.

Similarly, The Goldman Sachs Group, Inc. (GS - Free Report) agreed to acquire Industry Ventures, a leading venture capital platform that invests across all stages of the venture capital lifecycle. The move underscores Goldman’s strategic intent to expand its exposure to the innovation economy and further solidify its position in the global alternatives market.

The planned acquisition of Industry Ventures underscores Goldman’s strategic intent to strengthen its position in private markets and expand access to high-growth technology companies for clients globally. The deal is a well-thought-out step in the company’s long-term strategy to strengthen its $540 billion alternatives business, which spans private equity, growth capital, infrastructure, credit and real estate.

Item 1 of 2 RTX logo is seen in this illustration taken July 26, 2025. REUTERS/Dado Ruvic/Illustration/File Photo

[1/2]RTX logo is seen in this illustration taken July 26, 2025. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

ROME, Nov 10 (Reuters) - Raytheon and Lockheed Martin

(LMT.N), opens new tab will be the major customers of Avio's

(AVI.MI), opens new tab planned solid rocket motor plant in the United States, the Italian rocket maker said on Monday.

Raytheon, which is the defence arm of aerospace giant RTX

(RTX.N), opens new tab, and Lockheed Martin will have preferred access to a share of production at the plant, Avio said in separate statements on the two agreements.

Sign up here.

Avio has not announced where the plant will be built but has said it will be operational by early 2028.

"This agreement will help establish an additional supplier of solid rocket motors within the U.S.," said Bob Butz, Vice President of Operations, Supply Chain and Quality at Raytheon.

Avio will direct 80% of an ongoing 400 million euro ($466.48 million) capital increase for development of the site, its CEO told Reuters in October.

"The establishment of Avio’s SRM facility will allow us to bring our proven solid propulsion expertise to the United States, contributing to the innovation and development of a critical industrial supply chain," Jim Syring, CEO of Avio USA, said.

The solid rocket motor (SRM) market is growing due to rising military spending globally, particularly for missiles and tactical weapon systems, as countries aim to upgrade their defence capabilities with advanced missile technologies.

The President of Lockheed Martin Missiles and Fire Control Tim Cahill said the collaboration with Avio would allow the group to commit to a "diverse, resilient supply chain for solid rocket motors".

Avio CEO Giulio Ranzo told Reuters that the two deals were "fundamental, and give great solidity" to Avio's U.S. plan.

They come right after Italian state-controlled defence group Leonardo

(LDOF.MI), opens new tab cut its share in Avio to a little more than 19% and said last week that it was not interested in investing further in the group because it is already part of European missile maker MBDA.

($1 = 0.8575 euros)

Reporting by Giulia Segreti; Editing by Susan Fenton

Our Standards: The Thomson Reuters Trust Principles., opens new tab

It struck me how confident Amazon seemed heading into the holidays. When I told Lee about their plan to hire 250,000 seasonal workers, he didn't hesitate.

Apple (NASDAQ:AAPL) stock has been a surprisingly good performer in the last few months, thanks in part to some decent quarterly earnings results and optimism about iPhone 17 going into the holidays and beyond.

Northern Data AG (OTC:NDTAF) M&A Call November 10, 2025 9:00 AM EST

Company Participants

Shannon Devine - Executive of Investor Relations
Christopher Pavlovski - Founder, Chairman & CEO
Paolo Ardoino

Conference Call Participants

Jason Helfstein - Oppenheimer & Co. Inc., Research Division
Francesco Marmo

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to the Rumble update call. [Operator Instructions] Please note this event is being recorded.

I will now turn the conference over to Shannon Devine, Investor Relations for Rumble. Please go ahead.

Shannon Devine
Executive of Investor Relations

Thank you, operator. I'm here today with Chris Pavlovski, Founder, Chairman and CEO of Rumble; and Paolo Ardoino, CEO of Tether; and Zachary Lyons, Deputy CIO of Tether.

Before we begin the formal presentation, I would like to remind everyone that statements made on this call may include predictions, estimates or other information that might be considered forward-looking. All forward-looking statements are made only as of the date of this call and should be considered in conjunction with the company's cautionary statements in our press release and the factors included in our SEC filings. Future company updates will be available via press releases and the company's identified social media channels.

I will now turn the call over to Rumble's Founder, Chairman and CEO, Chris Pavlovski.

Christopher Pavlovski
Founder, Chairman & CEO

Thank you, Shannon. Good morning, and thank you for joining us. I couldn't be more excited to be here today and have Paolo, the CEO of Tether, alongside me. Today marks one of the most important days in Rumble's history. Last night, we announced 3 transformational milestones that will forever redefine who we are and where we're headed.

One, our exchange offer for Northern Data. This redefines what Rumble is. We become an instant AI infrastructure leader with land, lots of power, data centers and

Recommended For You

Tesla’s Cybertruck chief is leaving the company after more than eight years, the latest in a string of high-profile departures that have plagued the electric-vehicle maker.

Siddhant Awasthi announced his exit from Elon Musk’s automaker late Sunday. 

He started at Tesla as an intern, working his way up to lead the Cybertruck division from the engineering stage to mass production. He also recently took on the Model 3 program.

Siddhant Awasthi, head of the Cybertruck program, is leaving the company. Christopher Sadowski
Awasthi’s responsibilities included leading efforts in product strategy, quality enhancements and supply chain management, according to his LinkedIn profile.

Tesla reported record deliveries in the third quarter as American customers rushed to take advantage of $7,500 tax credits on EV purchases.

But analysts are widely expecting the automaker to suffer a steep sales slump in the fourth quarter since that incentive expired on Sept. 30.

In an attempt to boost sales, Tesla has been offering thousands of dollars worth of discounts on its vehicles over the past few months.

The automaker has suffered several blows as top execs have fled the firm en masse.

Troy Jones, top sales executive in North America, left the firm in July. He spent 15 years with the company, The Wall Street Journal earlier reported. 

His departure came less than a month after Omead Afshar, Musk’s top aide, fled the company.

Siddhant Awasthi ran the Cybertruck and Model 3 programs. LinkedIn/Siddhant Awasthi
Over the summer, Tesla also lost Jenna Ferrua, a human resources executive overseeing the North America division. 

Milan Kovac, the firm’s top AI executive, also left the company earlier this year.

It has been trampled by increased EV competition, especially from Chinese firms like BYD – an embarrassing topple after Musk once scoffed at the idea that BYD could ever be a rival.

Elon Musk once scoffed at the idea that Chinese firm BYD could be a rival. AP
But the company has surpassed Tesla to become the world’s largest manufacturer of EVs, pushing past $100 billion in revenue for the first time last year.

While Musk’s stint at the Department of Government Efficiency – his White House cost-cutting agency – only lasted 130 days, it appeared to create brand damage across his portfolio.

Angry demonstrators have set Tesla vehicles ablaze and vandalized showrooms, even hosting a protest on the opening day of Musk’s Tesla diner in Hollywood.

Tesla execs have largely shrugged off the matter, saying its Full Self-Driving technology and humanoid robots stand to make a mint.

Shareholders approved Musk’s $1 trillion pay package last week after he threatened to leave the company if he didn’t get it.

The staggering pay package is the largest on record, and hinges on a series of lofty performance metrics being reached over the next decade.

-

FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in a fireside chat at the UBS Global Healthcare Conference, November 9 - 12, 2025, in Palm Beach Gardens, Florida.

In connection with the conference, there will be an online webcast of the Company’s presentation available on the Company’s website starting at 1:45 p.m. Central Time / 2:45 p.m. Eastern Time on Tuesday, November 11, 2025.

The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentation will also be available on the Company’s website for 30 days.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2025, Acadia operated a network of 278 behavioral healthcare facilities with approximately 12,500 beds in 40 states and Puerto Rico. With approximately 25,500 employees serving more than 82,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

More News From Acadia Healthcare Company, Inc.

Back to Newsroom

SMR's Q3 loss widens sharply, but major Small Modular Reactor deals with TVA and RoPower highlight long-term clean energy potential.

SummaryScholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset.SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy.The recent stock correction was due to manufacturing site issues, not clinical setbacks; approval is expected by 2026, presenting a speculative buy opportunity.Key risks include manufacturing delays and competition, but the pipeline and broad label potential make SRRK an attractive, de-risked neuromuscular play for risk-tolerant investors.I initiate Scholar Rock with a buy rating at $88 target price. Getty Images

We Initiate Coverage On Scholar Rock With A Buy I initiate Scholar Rock with a speculative buy rating, as I believe Apitegromab is a de-risked asset, and the recent sell-off due to CRL is overdone. I plan to hold Scholar

Analyst’s Disclosure:I/we have a beneficial long position in the shares of SRRK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I do not provide personal investment advice. All content in this article, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strategies, is for informational and educational purposes only and should not be interpreted as financial or investment advice. While I strive to provide accurate and up-to-date information, the content may contain errors, inaccuracies, or omissions. Any financial decisions or investments made based on the information presented in this article are solely at your own risk. I am not responsible for any financial losses, damages, or other consequences resulting from actions taken in reliance on the information provided. You should conduct your own due diligence and consult with a qualified financial professional before making any investment decisions. This article reflects my personal views and opinions and is not affiliated with any employer, financial institution, or advisory firm. No representations or warranties are made regarding the completeness, accuracy, or reliability of the content, including any external links provided. Any third-party links are for informational purposes only, and I do not endorse or take responsibility for the content or services offered by external sources. All information is provided on an "as is" basis without any express or implied warranties.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Key Takeaways Novo Nordisk agreed with the U.S. Administration to lower Ozempic and Wegovy prices from 2026.The deal aims to broaden access through Medicare Part D, Medicaid, and direct-to-patient channels.Novo Nordisk expects a low single-digit sales hit in 2026 as it faces margin and competitive pressures.
Novo Nordisk (NVO - Free Report) is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity).

Following President Trump’s comments last month on forthcoming government action to reduce the prices of Ozempic and Wegovy, Novo Nordisk disclosed last week that it has reached an agreement with the U.S. Administration to implement price reductions beginning in 2026. The agreement is designed to broaden access and improve affordability for semaglutide therapies, including Wegovy and Ozempic, across Medicare Part D, Medicaid, and the direct-to-patient cash channel.

These drugs, which currently cost over $1,000 per month, will be priced at $350 through TrumpRx, a federal government website, slated to launch in early 2026, with future oral versions offered at $150 if approved. The Medicare Part D coverage for anti-obesity medicines will be introduced through a new pilot program expected to reach most Part D beneficiaries, while Novo Nordisk will benefit from a three-year tariff exemption. Trump’s negotiated cuts will allow Medicare and Medicaid to pay $245 for Ozempic and Wegovy, enabling coverage of Wegovy and Zepbound, with Medicare patients paying a $50 monthly co-pay.

NVO emphasized that these measures will expand access through improved affordability for semaglutide therapies, particularly authentic Wegovy, within Medicare. Novo Nordisk anticipates a direct, low single-digit negative impact on global sales growth in 2026 as implementation begins, with full financial guidance for 2026 to be provided alongside full-year 2025 results, to be announced on Feb. 4, 2026. The company and the U.S. Administration will now work to finalize the agreement’s operational details.

However, there’s still room for concern. Lower prices for Ozempic and Wegovy also introduce meaningful uncertainty around the long-term economics of GLP-1 development. A mandated pricing reset in the United States, NVO’s most important obesity market, compresses the profitability of its two largest revenue contributors at a time when the company is already contending with slowing demand trends, rising competitive pressure from Eli Lilly (LLY - Free Report) , and persistent headwinds from compounded semaglutide alternatives. Against this backdrop, the incremental volumes generated through expanded Medicare coverage may not fully offset the margin erosion expected once price reductions take effect.

These pressures also raise broader concerns about Novo Nordisk’s competitive positioning and its ability to sustain innovation within its core franchises. Following its July 2025 guidance cut and the September restructuring program targeting 9,000 job reductions, the company has already signaled a need to rebalance costs, streamline operations, and refocus capital allocation. A sharp decline in GLP-1 pricing could further strain financial flexibility and, over time, dampen incentives for continued R&D investment in next-generation therapeutics. While the new agreement may expand patient reach, it simultaneously heightens execution risk and adds another layer of uncertainty to NVO’s medium-term growth trajectory.

NVO’s Peers in the Obesity SpaceEli Lilly is Novo Nordisk’s fierce competitor in the diabetes/obesity space, which markets its tirzepatide-based drugs, Mounjaro (T2D) and Zepbound (obesity). Despite being on the market for less than three years, Mounjaro and Zepbound have become LLY’s key top-line drivers. In the first nine months of 2025, the drugs generated combined sales of $24.8 billion, accounting for 54% of Eli Lilly’s total revenues. LLY’s Mounjaro and Zepbound follow a dual mechanism of action as a GIP and GLP-1 RA.

Several other companies, like Viking Therapeutics (VKTX - Free Report) , are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Viking Therapeutics’ dual GIPR/GLP-1 RA, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. In August 2025, VKTX announced mixed top-line results from a mid-stage study evaluating the safety and efficacy of the oral formulation of VK2735, which caused the stock to drop significantly. Viking Therapeutics plans to meet with the FDA before this year’s end to discuss the next steps for oral VK2735. Phase III obesity studies with the subcutaneous formulation of VK2735 are currently underway.

NVO Stock’s Price, Valuation & EstimatesYear to date, Novo Nordisk shares have lost 46.9% against the industry’s 6.4% growth. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.

NVO Stock Underperforms the Industry, Sector & the S&P 500Image Source: Zacks Investment Research

Novo Nordisk is trading at a discount to the industry, as seen in the chart below. Going by the price/earnings ratio, the company’s shares currently trade at 11.80 forward earnings, which is lower than 15.57 for the industry. The stock is trading much below its five-year mean of 29.25.

NVO Stock ValuationImage Source: Zacks Investment Research

Earnings estimates for 2025 have deteriorated from $3.85 to $3.67 per share over the past 60 days. During the same time frame, Novo Nordisk’s 2026 earnings per share estimates have declined from $3.96 to $3.91.

NVO Estimate MovementImage Source: Zacks Investment Research

Novo Nordisk currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

American Vanguard Corporation (AVD) Q3 2025 Earnings Call November 10, 2025 9:00 AM EST

Company Participants

Anthony Young - Director of Investor Relations
Douglas Kaye - Chairman & CEO
David Johnson - Chief Financial Officer

Conference Call Participants

Michael Harrison - Seaport Research Partners
Wayne Pinsent - The Gabelli Healthcare & Wellness Trust
Charles Rose
Dmitry Silversteyn - Water Tower Research LLC

Presentation

Operator

Greetings, and welcome to the American Vanguard Third Quarter 2025 Earnings Conference Call. [Operator Instructions] And please note, this conference is being recorded.

I will now turn the conference over to your host, Mr. Anthony Young, Director of Investor Relations. Sir, the floor is yours.

Anthony Young
Director of Investor Relations

Thank you, operator. Good morning, and welcome to American Vanguard's Third Quarter 2025 Earnings Review. Our prepared remarks will be led by Dak Kaye, Chief Executive Officer; and David Johnson, Chief Financial Officer. A copy of today's release, along with supplemental slides, are available on our website. A replay of the webcast and transcript from this event will be available on our website shortly as well.

Before we begin our comments, we'd like to remind everyone that today's press release and certain of our comments on the call include non-GAAP figures and forward-looking statements, and actual results may differ materially. Please refer to the cautionary language included in our press release and slides and to the risk factors described in our SEC filings, all of which are available on our website.

It is now my pleasure to turn the call over to CEO, Dak Kaye.

Douglas Kaye
Chairman & CEO

Thank you, Anthony, and welcome, everyone, to our third quarter 2025 earnings conference call. When I joined the team 11 months ago, my directive was simplify, prioritize and deliver, and that is what we are doing. Our adjusted EBITDA increased from $1.8 million in the year ago period

Recommended For You

Nothing concentrates the mind like a suitor in the wings.

After ITV PLC (LSE:ITV) last week confirmed Comcast is in talks to buy the UK broadcaster's Media & Entertainment arm (the broadcast and streaming bit), UBS ran the numbers on what that could mean, while keeping a cool head and a 'sell' rating with a 12-month target of 72p, 7p lower than the current price.

Starting with the valuation, the figure touted for the M&E arm is £1.6 billion on an enterprise valuation basis. UBS’s discounted cash flow (DCF) is £1.5 billion, roughly in the same ballpark at eight times forecast 2026 operating profit.

If ITV banked this and used all of it to buy back shares, earnings per share (EPS) could be lifted to about 10p versus a 7.7p otherwise; more than 20% accretive.

On that arithmetic, the shares would trade on roughly seven times EPS, cheaper than listed peer Banijay at nine times.

There are plenty of caveats, though: There has not yet been a firm bid, and management has previously talked up the value of keeping production and distribution under one roof.

That's not to mention that any deal would face intense regulatory scrutiny, as the UK’s biggest commercial public broadcaster could end up owned by a non-UK group, with Comcast already owning Sky.

UBS also tweaked its model after ITV’s third-quarter update: revenue was better, mostly timing in Studios, but guidance for fourth-quarter TV total advertising revenue (TAR) was soft at minus 9% year on year.

One-off cost savings of £35 million are planned in 2025. Net effect: 2025 EPS nudged up 2%, 2026 cut 5% to 7.75p, assuming 2026 TAR grows 2% and no extra savings.

Howard Hughes Holdings (HHH - Free Report) reported $390.24 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 19.3%. EPS of $2.02 for the same period compares to $1.95 a year ago.

The reported revenue represents a surprise of +17.71% over the Zacks Consensus Estimate of $331.53 million. With the consensus EPS estimate being $1.56, the EPS surprise was +29.49%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Howard Hughes Holdings performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Master Planned Community land sales: $248.47 million compared to the $199.43 million average estimate based on two analysts. The reported number represents a change of +25.3% year over year.Revenues- Operating Assets Segment: $117.18 million versus $114.18 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.8% change.Revenues- Master Planned Communities Segment: $271.58 million versus the two-analyst average estimate of $217.38 million. The reported number represents a year-over-year change of +27.7%.Segment EBT- Master Planned Communities: $205.01 million compared to the $153.59 million average estimate based on two analysts.View all Key Company Metrics for Howard Hughes Holdings here>>>

Shares of Howard Hughes Holdings have returned +2.3% over the past month versus the Zacks S&P 500 composite's +0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Let's take a look at what these Wall Street heavyweights have to say about Blue Bird (BLBD - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Blue Bird currently has an average brokerage recommendation (ABR) of 1.63, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by eight brokerage firms. An ABR of 1.63 approximates between Strong Buy and Buy.

Of the eight recommendations that derive the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.5% and 12.5% of all recommendations.

Brokerage Recommendation Trends for BLBD

Check price target & stock forecast for Blue Bird here>>>

While the ABR calls for buying Blue Bird, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is BLBD a Good Investment?Looking at the earnings estimate revisions for Blue Bird, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.04.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Blue Bird. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Blue Bird.

Petrobras (PBR - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PBR broke through the 200-day moving average, which suggests a long-term bullish trend.

The 200-day simple moving average helps traders and analysts determine overall long-term market trends for stocks, commodities, indexes, and other financial instruments. The indicator moves higher or lower along with longer-term price moves, serving as a support or resistance level.

PBR could be on the verge of another rally after moving 10.9% higher over the last four weeks. Plus, the company is currently a Zacks Rank #3 (Hold) stock.

Looking at PBR's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 2 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.

Investors may want to watch PBR for more gains in the near future given the company's key technical level and positive earnings estimate revisions.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Let's take a look at what these Wall Street heavyweights have to say about Dell Technologies (DELL - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Dell Technologies currently has an average brokerage recommendation (ABR) of 1.52, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 22 brokerage firms. An ABR of 1.52 approximates between Strong Buy and Buy.

Of the 22 recommendations that derive the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 68.2% and 9.1% of all recommendations.

Brokerage Recommendation Trends for DELL

Check price target & stock forecast for Dell Technologies here>>>

The ABR suggests buying Dell Technologies, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in DELL?Looking at the earnings estimate revisions for Dell Technologies, the Zacks Consensus Estimate for the current year has increased 0.1% over the past month to $9.54.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Dell Technologies. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Dell Technologies may serve as a useful guide for investors.

For the quarter ended September 2025, Telephone & Data Systems (TDS - Free Report) reported revenue of $308.52 million, down 74.8% over the same period last year. EPS came in at $0.07, compared to $0.01 in the year-ago quarter.

The reported revenue represents a surprise of -23.31% over the Zacks Consensus Estimate of $402.31 million. With the consensus EPS estimate being -$0.06, the EPS surprise was +216.67%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how TDS performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

TDS Telecom Residential connections - Broadband - Wireline, Incumbent: 225.5 thousand versus 228.87 thousand estimated by two analysts on average.TDS Telecom Residential connections - Broadband - Wireline, Expansion: 150.7 thousand versus the two-analyst average estimate of 154.62 thousand.TDS Telecom Residential connections - Broadband - Cable: 186.1 thousand versus the two-analyst average estimate of 186.41 thousand.TDS Telecom Residential connections - Broadband - Total: 562.4 thousand versus the two-analyst average estimate of 569.9 thousand.Operating Revenues- TDS Telecom- Service: $254.97 million versus $261.39 million estimated by three analysts on average.Operating Revenues- TDS Telecom: $255.11 million versus the three-analyst average estimate of $261.45 million.Operating Revenues- All other: $6.29 million versus $5.46 million estimated by three analysts on average.Operating Revenues- TDS Telecom- Service- Residential - Wireline, Expansion: $39.61 million versus the two-analyst average estimate of $36.96 million.Operating Revenues- TDS Telecom- Service- Residential - Cable: $60.23 million compared to the $62.29 million average estimate based on two analysts.Revenues from contracts with customers- Total- Service - Residential: $181.75 million versus $185.57 million estimated by two analysts on average.Revenues from contracts with customers- Total- Service - Commercial: $34.07 million compared to the $34.93 million average estimate based on two analysts.Revenues from contracts with customers- Total- Service - Wholesale: $38.37 million versus $42.34 million estimated by two analysts on average.View all Key Company Metrics for TDS here>>>

Shares of TDS have returned -1.6% over the past month versus the Zacks S&P 500 composite's +0.3% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Tutor Perini (TPC - Free Report) .

Tutor Perini currently has an average brokerage recommendation (ABR) of 1.40, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by five brokerage firms. An ABR of 1.40 approximates between Strong Buy and Buy.

Of the five recommendations that derive the current ABR, four are Strong Buy, representing 80% of all recommendations.

Brokerage Recommendation Trends for TPC

Check price target & stock forecast for Tutor Perini here>>>

While the ABR calls for buying Tutor Perini, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is TPC Worth Investing In?In terms of earnings estimate revisions for Tutor Perini, the Zacks Consensus Estimate for the current year has increased 6.1% over the past month to $4.01.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Tutor Perini. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Tutor Perini may serve as a useful guide for investors.

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.

The Zacks Premium service makes this easier. It features daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All of these can help you quickly identify what stocks to buy, what to sell, and what are today's hottest industries.

It also includes the Focus List, a long-term portfolio of top stocks that have all the elements to beat the market.

Breaking Down the Zacks Focus ListIf you could, wouldn't you jump at the chance for access to a curated list of stocks to kickstart your investing journey?

That's what the Zacks Focus List offers. It's a portfolio of 50 stocks that serve as a starting point for long-term investors to build their individual portfolios. The stocks included in the list are set to outperform the market over the next 12 months.

What makes the Focus List even more helpful is that each selection is accompanied by a full Zacks Analyst Report, which explains the reasoning behind every stock's selection and why we believe it's a good pick for the long-term.

The portfolio's past performance only solidifies why investors should consider it as a starting point. For 2020, the Focus List gained 13.85% on an annualized basis compared to the S&P 500's return of 9.38%. Cumulatively, the portfolio has returned 2,519.23% while the S&P returned 854.95%. Returns are for the period of February 1, 1996 to March 31, 2021.

Focus List MethodologyWhen stocks are picked for the Focus List, it reflects our enduring reliance on the power of earnings estimate revisions.

Brokerage analysts are in charge of determining a company's growth and profitability expectations, or earnings estimates. These analysts work together with company management to evaluate all factors that may affect future earnings, like interest rates, the economy, and sector and industry optimism.

What a company will earn down the road also needs to be taken into consideration, and this is why earnings estimate revisions are so important.

Stocks that receive upward earnings estimate revisions are more likely to receive even more upward changes in the future. For example, if an analyst raised their estimates last month, they're more likely to do it again this month, and other analysts are likely to do the same.

Harnessing the power of earnings estimate revisions is where the Zacks Rank comes in. The Zacks Rank, which is a unique, proprietary stock-rating model, employs earnings estimate revisions to make it easier to build a winning portfolio.

There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise. Each one of these features is then given a raw score that's recalculated every night and compiled into the Rank. Using this data, stocks are classified into five groups, ranging from "Strong Buy" to "Strong Sell."

The Focus List is comprised of stocks hand-picked from a long list of #1 (Strong Buy) or #2 (Buy) ranked companies, meaning that each new addition boasts a bullish earnings consensus among analysts.

Since stock prices respond to revisions, it can be very profitable to buy stocks with rising earnings estimates. By buying Focus List stocks, then, you're likely getting into companies whose future earnings estimates will be raised, potentially leading to price momentum.

Focus List Spotlight: HCA Healthcare (HCA - Free Report) HCA Healthcare is the largest non-governmental operator of acute care hospitals in the United States. Headquartered in Nashville, TN, it operates hospitals and related health care entities. At the end of 2024, the company operated 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

Since being added to the Focus List on January 7, 2019 at $123.39 per share, shares of HCA have increased 286.26% to $476.61. The stock is currently a #1 (Strong Buy) on the Zacks Rank.

Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $1.04 to $27.21. HCA also boasts an average earnings surprise of 12.4%.

Moreover, analysts are expecting HCA's earnings to grow 23.9% for the current fiscal year.

Reveal Winning StocksUnlock all of our powerful research, tools and analysis, including the Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. You'll quickly identify which stocks to buy, hold and sell, and target today's hottest industries, to help improve the performance of your portfolio. Gain full access now >>

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Let's take a look at what these Wall Street heavyweights have to say about Celestica (CLS - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Celestica currently has an average brokerage recommendation (ABR) of 1.47, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.47 approximates between Strong Buy and Buy.

Of the 17 recommendations that derive the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 70.6% and 11.8% of all recommendations.

Brokerage Recommendation Trends for CLS

Check price target & stock forecast for Celestica here>>>

While the ABR calls for buying Celestica, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Should You Invest in CLS?Looking at the earnings estimate revisions for Celestica, the Zacks Consensus Estimate for the current year has increased 7.9% over the past month to $5.9.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Celestica. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Celestica may serve as a useful guide for investors.

After reaching an important support level, Pebblebrook Hotel (PEB - Free Report) could be a good stock pick from a technical perspective. PEB surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

One of the three major moving averages, the 50-day simple moving average is commonly used by traders and analysts to determine support or resistance levels for different types of securities. However, the 50-day is considered to be more important since it's the first marker of an up or down trend.

Over the past four weeks, PEB has gained 10.8%. The company is currently ranked a Zacks Rank #2 (Buy), another strong indication the stock could move even higher.

Looking at PEB's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 5 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.

Investors should think about putting PEB on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.